Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    RUC-4

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zalunfiban At First Contact Reduced Severe Heart Damage Risk
    Zalunfiban At First Contact Reduced Severe Heart Damage Risk

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rapid-zalunfiban-treatment-at-1st-point-of-medical-contact-lowered-risk-of-more-severe-heart-damage-in-combination-with-other-serious-heart-attack-complications-302608665.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Novel Anti-Platelet Drug Phase 3 Study For Heart Attack Shows
    Novel Anti-Platelet Drug Phase 3 Study For Heart Attack Shows

    23 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/phase-3-study-of-novel-anti-platelet-drug-for-heart-attack-reports-positive-topline-results-302563949.html

    PR NEWSWIRE
    23 Sep 2025
    Share Share
    Celecor Finishes Multinational Phase 3 Study of Heart Attack
    Celecor Finishes Multinational Phase 3 Study of Heart Attack

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/celecor-completes-multinational-phase-3-registrational-study-of-novel-anti-platelet-agent-for-heart-attack-302464566.html

    PR NEWSWIRE
    27 May 2025
    Share Share